In a pooled analysis of NACT trials, Denkert and colleagues found a significantly longer disease-free survival in the HER2-positive group for tumours with high TILs [13], which was also shown by Heppner et al. [19] and Loi et al. [20]. Here, ERBB2 is linked to neoplasm.